Ozempic 0.5 mg solution for injection in pre-filled pen

The safety and efficacy of acute subcutaneous administration of semaglutide in non-diabetic patients with acute ischemic stroke: a multicentre, phase 2, prospective, randomized, open-label, blinded endpoint trial (ASSET)

A randomised, controlled, parallel group, open-label trial evaluating the impact of treatment with the GLP-1 analogue semaglutide on weight loss in people living with HIV and obesity (SWIFT Study)

Efficacy, safety, and pharmacokinetics of NNC0519-0130 once weekly s.c. versus semaglutide 1.0 mg and placebo in people with chronic kidney disease, with or without type 2 diabetes, and with overweight or obesity: a proof-of-concept and dose-finding study

The SEMAFOOT2 Pilot. Effect of semaglutide on healing of foot ulcers in type 2 diabetes patients. A Pilot study.

An open-label, single-center, non-controlled pilot clinical trial to assess the efficacy of weekly semaglutide in combination with regular counselling sessions to reduce craving and use of chemsex associated drugs (CoSem4Chemsex) study.

Protocol Title: Efficacy and safety of once-weekly subcutaneous NNC0662-0419 in participants with type 2 diabetes – a dose-finding study

Efficacy and safety of once-weekly subcutaneous UBT251 in participants with type 2 diabetes – a dose-finding study

A randomised double-blind placebo-controlled clinical study investigating the effects of semaglutide s.c. once-weekly versus placebo on central and peripheral inflammation in participants with Alzheimer’s disease.

Multifactorial intervention to reduce cardiovascular disease in type 1 diabetes

TOLEDDO: Effect of weekly GLP1 agonist treatment in "double diabetes": a randomized, open-label study

Semaglutide for people with obesity and resistant hypertension (SUPPORT): a pilot, randomized, parallel-group, integrated, multicentre clinical trial.

Screening and intervention for subclinical coronary artery disease in patients with type 2 diabetes: THE STENO INTEN-CT STUDY

Glucagone Like Peptide-1 Receptor (GLP-1R) Analogue Assisted Rapid Weight Loss Program as treatment of Idiopathic Intracranial Hypertension

Open-label, double-arm, controlled, randomized, multicentre clinical trial to evaluate the impact of pharmacogenetic-guided treatment in patients with insufficiently controlled type 2 diabetes

Semaglutide and Finerenone for Kidney and Vascular Protection in CKD

Healing Diabetic Foot Ulcers with Semaglutide

Using GLP-1 to prevent Post-Transplantation Diabetes Mellitus